share_log

復星醫藥：聯合公告(1)以吸收合併復宏漢霖之方式由復星新藥對復宏漢霖附前提條件私有化之建議及(2)建議撤銷上市達成潛在股份選擇要約的前提條件

FOSUN PHARMA: JOINT ANNOUNCEMENT (1) PROPOSED PRE-CONDITIONAL PRIVATISATION OF HENLIUS BY FOSUN NEW MEDICINE BY WAY OF MERGER BY ABSORPTION OF HENLIUS AND (2) PROPOSED WITHDRAWAL OF LISTING FULFILMENT OF PRE-CONDITION TO THE POTENTIAL SHARE ALTERNATIVE OFFER

HKEX ·  Jul 11, 2024 18:06

Summary by Futu AI

上海復星醫藥（集團）有限公司（以下簡稱「復星醫藥」）於2024年7月11日宣布，已達成對其子公司上海復宏漢霖生物技術股份有限公司（以下簡稱「復宏漢霖」，股份代號：02696）的私有化前提條件。此次私有化建議是通過吸收合併的方式進行，由復星醫藥旗下的上海復星新藥研究有限公司（以下簡稱「復星新藥」）提出。根據公告，要約人已於2024年7月10日下午4時前收到足夠的意向書，持股量達到了最低接受條件的2%。然而，要約人保留最終決定是否提出潛在股份選擇要約的酌情權。合併協議的生效仍然是一種可能性，並須待聯合公告所載實施條件達成或獲豁免後方可實施。復星醫藥提醒股東及潛在投資者，在買賣證券時應謹慎行事。
上海復星醫藥（集團）有限公司（以下簡稱「復星醫藥」）於2024年7月11日宣布，已達成對其子公司上海復宏漢霖生物技術股份有限公司（以下簡稱「復宏漢霖」，股份代號：02696）的私有化前提條件。此次私有化建議是通過吸收合併的方式進行，由復星醫藥旗下的上海復星新藥研究有限公司（以下簡稱「復星新藥」）提出。根據公告，要約人已於2024年7月10日下午4時前收到足夠的意向書，持股量達到了最低接受條件的2%。然而，要約人保留最終決定是否提出潛在股份選擇要約的酌情權。合併協議的生效仍然是一種可能性，並須待聯合公告所載實施條件達成或獲豁免後方可實施。復星醫藥提醒股東及潛在投資者，在買賣證券時應謹慎行事。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (HEREINAFTER REFERRED TO AS “FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 11 JULY 2024 THAT IT HAS REACHED THE PREREQUISITES FOR THE PRIVATIZATION OF ITS SUBSIDIARY SHANGHAI FUHUNG HANLIN BIOTECHNOLOGY CO., LTD. (HEREINAFTER REFERRED TO AS “FUHONG HANLIN”, STOCK CODE: 02696). THIS PRIVATIZATION PROPOSAL IS CARRIED OUT BY ABSORPTION COMBINED METHOD, PROPOSED BY SHANGHAI FUSTAR NEW DRUG RESEARCH CO., LTD. (HEREINAFTER REFERRED TO AS “FUSTAR NEW MEDICINE”) UNDER THE SUBSIDIARY OF FUSTAR PHARMACEUTICALS. According to the announcement, a sufficient letter of intent was received by 4 pm on 10 July 2024 for the holding to reach 2% of the minimum acceptance criteria. HOWEVER, THE CONTRACTOR RESERVES THE DISCRETION OF THE FINAL DECISION ON WHETHER TO SUBMIT A PROSPECTIVE SHARE OPTION OFFER. The Merger Agreement remains a possibility and is subject to the fulfilment of the implementing conditions set out in the Joint Announcement or its subsequent exemption. FUSTAR PHARMACEUTICALS REMINDS SHAREHOLDERS AND POTENTIAL INVESTORS TO EXERCISE CAUTION WHEN TRADING SECURITIES.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (HEREINAFTER REFERRED TO AS “FUSTAR PHARMACEUTICALS”) ANNOUNCED ON 11 JULY 2024 THAT IT HAS REACHED THE PREREQUISITES FOR THE PRIVATIZATION OF ITS SUBSIDIARY SHANGHAI FUHUNG HANLIN BIOTECHNOLOGY CO., LTD. (HEREINAFTER REFERRED TO AS “FUHONG HANLIN”, STOCK CODE: 02696). THIS PRIVATIZATION PROPOSAL IS CARRIED OUT BY ABSORPTION COMBINED METHOD, PROPOSED BY SHANGHAI FUSTAR NEW DRUG RESEARCH CO., LTD. (HEREINAFTER REFERRED TO AS “FUSTAR NEW MEDICINE”) UNDER THE SUBSIDIARY OF FUSTAR PHARMACEUTICALS. According to the announcement, a sufficient letter of intent was received by 4 pm on 10 July 2024 for the holding to reach 2% of the minimum acceptance criteria. HOWEVER, THE CONTRACTOR RESERVES THE DISCRETION OF THE FINAL DECISION ON WHETHER TO SUBMIT A PROSPECTIVE SHARE OPTION OFFER. The Merger Agreement remains a possibility and is subject to the fulfilment of the implementing conditions set out in the Joint Announcement or its subsequent exemption. FUSTAR PHARMACEUTICALS REMINDS SHAREHOLDERS AND POTENTIAL INVESTORS TO EXERCISE CAUTION WHEN TRADING SECURITIES.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated